BMJ:强烈建议SpO2≥96%的患者停止氧疗

2018-10-31 佚名 中国循环杂志

住了院,吸吸氧,很常见,但近日一份由国家专家小组发表在BMJ的指南指出,住院患者还是不推荐常规氧气治疗,认为获益不确定并有一定危害。

住了院,吸吸氧,很常见,但近日一份由国家专家小组发表在BMJ的指南指出,住院患者还是不推荐常规氧气治疗,认为获益不确定并有一定危害。

上述建议是“站在”最新循证医学证据上的,且被列入BMJ“快速建议(Rapid Recommendations)”计划。

所谓的“快速建议”计划,就是根据最新证据提出快速、有信的指导意见,来帮助医生做出最好的治疗决策。

当前,氧疗在院内常用,而且很多患者在血氧饱和度正常时给予了氧疗,比如正常人血氧饱和度(SpO2)通常在96%~98%,而院内患者常因氧疗接近100%。而且氧疗时,何时启动何时终止也很少被注意。

Lancet上发表的一项研究就此进行了探索,并发现,给予正常血氧水平的患者以氧疗,会增加死亡率。研究者由此认为,氧疗需保守,但并没有做出具体建议。

BMJ的这份指南就此对Lancet上这项研究进行了分析,并提出下属意见:



强烈建议SpO2≥96%的患者停止氧疗;

心梗或脑卒中患者,SpO2在90%~92%建议不启动氧疗,强烈建议SpO2≥93%不启动氧疗;

对于其他疾病如感染,尚无充足证据明确显示氧疗何时启动氧疗;

对于大多数患者,SpO2目标为90%~94%似乎是合理的,至少可以避免危害;

对于存在高碳酸血症性呼吸衰竭风险的患者,推荐目标为 88%~92%;

对于不同患者,建议使用所需的最少氧气量。

指南指出,上述意见适用于大多数患者,但不适用于手术患者、婴儿或其他罕见病患者。并且,随着新证据的出现,上述建议也或会改变。

我国专家也很重视合理氧疗,并于2018年发表了《急诊氧气治疗专家共识》。共识指出,合理氧疗能使患者获益,而不恰当氧疗,非但不能使患者获益甚至还有害处。

共识不推荐给予无低氧血症的患者氧疗,并建议任何情况下的氧疗均需同时记录吸氧浓度。

这份共识使用ESCAPE工具设定氧疗目标,其中E(Bronchi Ectasia)指支气管扩张;S(Spinal disease)指脊柱畸形或截瘫;C(Chest disease)指胸壁疾病;A(Airway obstructed diseas)指 气道阻塞性疾病(如COPD、哮喘、肺纤维化);P(Paralysis)指瘫痪(如神经肌肉接头疾病、药物过量);E(Elevated body weight)指体重增加(肥胖)。

对于怀疑或确诊心梗者,共识认为,若无低氧血症尚不能确定对缺血部位的心肌提供高浓度的氧是否可使患者获益,建议无ESCAPE 风险者维持血氧饱和度94%~98%,有ESCAPE风险的患者维持血氧饱和度88%~92%,氧疗应当基于以上目标谨慎使用。

对于休克患者,建议将SpO2 94%~98%作为理想目标。

急性脑卒中患者,SpO2正常者持续氧疗或夜间氧疗并不能使患者获益。对于无CO2潴留风险者血氧饱和度目标为94%~98%;存在CO2潴留者SpO2目标为88%~93%。可由鼻导管开始给予低浓度氧疗。

原始出处:

[1] Siemieniuk RAC, Chu DK, Ha-Yeon KimL, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ , 2018, 363: k4169.

[2] 急诊氧气治疗专家共识组. 急诊氧气治疗专家共识. 中华急诊医学杂志,2018, 27: 355-360.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1063938, encodeId=3e03106393885, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Oct 26 01:00:55 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848628, encodeId=7e05184862840, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Dec 11 21:44:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054747, encodeId=2f392054e4753, content=<a href='/topic/show?id=0c6616633f9' target=_blank style='color:#2F92EE;'>#SpO2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16633, encryptionId=0c6616633f9, topicName=SpO2)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Aug 23 15:44:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466546, encodeId=31a7146654654, content=<a href='/topic/show?id=621d6402097' target=_blank style='color:#2F92EE;'>#氧疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64020, encryptionId=621d6402097, topicName=氧疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a786841989, createdName=rgjl, createdTime=Thu Nov 01 16:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2021-10-26 452946589

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1063938, encodeId=3e03106393885, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Oct 26 01:00:55 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848628, encodeId=7e05184862840, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Dec 11 21:44:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054747, encodeId=2f392054e4753, content=<a href='/topic/show?id=0c6616633f9' target=_blank style='color:#2F92EE;'>#SpO2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16633, encryptionId=0c6616633f9, topicName=SpO2)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Aug 23 15:44:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466546, encodeId=31a7146654654, content=<a href='/topic/show?id=621d6402097' target=_blank style='color:#2F92EE;'>#氧疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64020, encryptionId=621d6402097, topicName=氧疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a786841989, createdName=rgjl, createdTime=Thu Nov 01 16:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-12-11 gaoxiaoe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1063938, encodeId=3e03106393885, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Oct 26 01:00:55 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848628, encodeId=7e05184862840, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Dec 11 21:44:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054747, encodeId=2f392054e4753, content=<a href='/topic/show?id=0c6616633f9' target=_blank style='color:#2F92EE;'>#SpO2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16633, encryptionId=0c6616633f9, topicName=SpO2)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Aug 23 15:44:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466546, encodeId=31a7146654654, content=<a href='/topic/show?id=621d6402097' target=_blank style='color:#2F92EE;'>#氧疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64020, encryptionId=621d6402097, topicName=氧疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a786841989, createdName=rgjl, createdTime=Thu Nov 01 16:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2019-08-23 若水123
  4. [GetPortalCommentsPageByObjectIdResponse(id=1063938, encodeId=3e03106393885, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Oct 26 01:00:55 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848628, encodeId=7e05184862840, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Dec 11 21:44:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054747, encodeId=2f392054e4753, content=<a href='/topic/show?id=0c6616633f9' target=_blank style='color:#2F92EE;'>#SpO2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16633, encryptionId=0c6616633f9, topicName=SpO2)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Aug 23 15:44:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466546, encodeId=31a7146654654, content=<a href='/topic/show?id=621d6402097' target=_blank style='color:#2F92EE;'>#氧疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64020, encryptionId=621d6402097, topicName=氧疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a786841989, createdName=rgjl, createdTime=Thu Nov 01 16:44:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-11-01 rgjl

相关资讯

Respirology:前额传感器测量血氧更接近于动脉血水平

A图为指套组传感器和动脉化毛细血管组的氧饱和度Bland-Altman一致性分析图。B图为前额传感器组和动脉化毛细血管组的氧饱和度Bland-Altman一致性分析图。空心圆代表静息状态下收集的数据,实心圆代表运动试验末期收集的数据。图中实线代表差值均数(-2%),虚线代表95%一致性界限(± 3%)。 COPD的血氧测定一般是通过脉搏血氧饱和度仪的指套传感器来测定,但是指套传感器在测量外

Stroke:可植入共振器监测肿瘤深处氧气含量

近日,一篇发表在国际杂志Stroke上的研究论文中,来自Norris Cotton综合癌症研究中心的研究人员通过研究开发了一种名为电子顺磁共振(EPR)血氧测定的新技术,该技术可帮助临床医生直接测定癌症及中风患者在高氧水平下的氧气含量,为规范疾病疗法有效改善患者的预后提供了一定的帮助。氧气对维持生命必不可少,细胞和组织中特定水平的氧气对于维持机体正常的功能非常重要,同时氧气在许多疾病的发生及疗法过